Trevi Therapeutics, Inc.
TRVI
$14.76
-$0.12-0.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.16M | 15.85M | 14.74M | 13.77M | 12.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.77M | 49.33M | 51.35M | 51.52M | 51.09M |
| Operating Income | -52.77M | -49.33M | -51.35M | -51.52M | -51.09M |
| Income Before Tax | -45.68M | -42.82M | -45.89M | -47.35M | -47.38M |
| Income Tax Expenses | -72.00K | -63.00K | -31.00K | -47.00K | -34.00K |
| Earnings from Continuing Operations | -45.61 | -42.76 | -45.86 | -47.30 | -47.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.61M | -42.76M | -45.86M | -47.30M | -47.35M |
| EBIT | -52.77M | -49.33M | -51.35M | -51.52M | -51.09M |
| EBITDA | -52.63M | -49.18M | -51.20M | -51.37M | -50.94M |
| EPS Basic | -0.32 | -0.32 | -0.37 | -0.42 | -0.45 |
| Normalized Basic EPS | -0.20 | -0.20 | -0.23 | -0.26 | -0.28 |
| EPS Diluted | -0.32 | -0.32 | -0.37 | -0.42 | -0.45 |
| Normalized Diluted EPS | -0.20 | -0.20 | -0.23 | -0.26 | -0.28 |
| Average Basic Shares Outstanding | 566.55M | 538.57M | 499.08M | 455.25M | 425.94M |
| Average Diluted Shares Outstanding | 566.55M | 538.57M | 499.08M | 455.25M | 425.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |